105 results about "Vinylene group" patented technology

The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I): wherein represents a single bond or a double bond; Ar1 represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R1 and R2 each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z1 represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing Aβ40 and Aβ42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ such as Alzheimer's disease or Down's syndrome.

The invention discloses a benzodifuran conjugated polymer material and a preparation method and application thereof. The structural formula of the polymer is shown by a formula I, wherein A1, A2, R1 and R2 separately represent hydrogen, alkyl group with 1-30 carbon atoms, alkoxyl group with 1-30 carbon atoms, cyano group, nitro group, carbonyl group, ester group, aryl group, aralkyl group, halogen, haloalkyl, heteroalkyl, alkenyl, and aryl or conjugation unit substituted by a substituent group containing single bond, double bond, triple bond or the combination thereof; and Ar is selected fromthe groups substituted or unsubstituted: vinylidene, ethynylene, monocycle arylene, bicyclo-arylene, arylene with three or more rings, monocyclic heteroarylene, bicyclo-heteroarylene, heteroarylene with three or more rings and 1-6 of the groups condensed or connected. The polymer material disclosed by the invention can be applied to the photoelectric field such as organic solar cells and high-shift field effect transistors. The formula I is shown in the specification.

The present invention offers novel cyclic diamine compounds and a pharmaceutical composition containing the same.The present invention relates to a compound represented by the formula (I) or salt(s) or solvate(s) thereof. (In the formula, is an optionally substituted divalent residue of benzene, pyridine, cyclohexane or naphthalene or is a vinylene group whereAr is an optionally substituted aryl group;X is —NH—, oxygen atom or sulfur atom;Y is —NR1—, oxygen atom, sulfur atom, sulfoxide or sulfone;Z is a single bond or —NR2—;R1 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group;R2 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group;l is an integer of from 0 to 15;m is an integer of 2 or 3; andn is an integer of from 0 to 3).The compound of the present invention is useful as a pharmaceutical composition, particuarly as an inhibitor of acyl coenzyme A cholesterol acyltransferase (ACAT).

In order to provide a lithium secondary battery having high terminal-to-terminal open circuit voltage at the end of charge, suppressed amount of evolved gas on continuous charge, and superior cycle characteristics, the electrolyte solution thereof comprises either both vinylethylene carbonate compound and vinylene carbonate compound, lactone compound having a substituent at its a position in an amount of 0.01 weight % or more and 5 weight % or less, lactones having an unsaturated carbon-carbon bond in an amount of 0.01 weight % or more and 5 weight % or less, or sulfonate compound represented by the formula below.In the formula, L represents a bivalent connecting group consisting of at least one carbon atom and hydrogen atoms, and R30 represents, independently of each other, an unsubstituted or fluorine-substituted aliphatic saturated hydrocarbon group.

A compound represented by the following formula (I′)wherein X1 is a methylene group, an ethylene group, a trimethylene group or a vinylene group, X2 is a divalent group represented by the following formula A or B,Y is an ethylene group or a vinylene group, m and n are each an integer of 0 to 7, which satisfy m+n=0 to 8, R1 and R2 are each independently a hydrogen atom, a methyl group or an ethyl group, provided that when X1 is a methylene group, then X2 is not a divalent group represented by the formula A, and when X1 is a vinylene group, then X2 is not a divalent group represented by the formula A. The compound is a stable capsinoid derivative, and is useful as an active ingredient of an external blood circulation enhancer or a cosmetic composition, a pharmaceutical composition, or a food composition.

The invention discloses a photoelectric active dithiophene benzodithiophene conjugated polymer and a preparation method and an application thereof. The structural formula of the polymer is shown as a formula I, wherein A1 and A2 independently represent any one of the following unsubstituted or substituent-containing groups: hydrogen, alkyl with 1-30 carbon atoms, alkoxyl with 1-30 carbon atoms, cyano-group, nitryl, ester group, aryl, aralkyl, halogen, haloalkyl, hetero-alkyl, vinyl, single bond, double bonds, triple bonds or combined substituent-substituted aryl; Ar is selected from any one of the following unsubstituted or substituent-containing groups: vinylidene, ethynylene, monocyclic ring arylidene, dicyclo-arylidene, arylidene containing at least three rings, monocyclic ring heteroarylidene, dicyclo-heteroarylidene and heteroarylidene containing at least three rings; and n represents the quantity of repeated units of the polymer, and is a natural number ranging from 5 to 1,000. The polymer provided by the invention has very high hole mobility and high photoelectric transformation efficiency.

It is an object of the present invention to provide a novel compound useful as a constituent of an organic EL element and the use of the compound permits the realization of a highly practical organic EL element whose driving voltage is substantially low and which has a low leakage current. Accordingly, the present invention herein provides a fluoranthene compound represented by the following general formula (1): A-L-B  (1) wherein A and B each represent a monovalent group having a fluoranthene structure represented by the following general formula (2), provided that A is linked to the group L present in the general formula (1), at the carbon atom selected from those specified by the numerical values of 7 to 10 appearing in Formula (2) and that B is linked to the group L present in Formula (1), at the carbon atom selected from those specified by the numerical values of 1 to 6 appearing in Formula (2): wherein L is a member selected from the group consisting of a single bond, substituted or unsubstituted arylene groups each having 6 to 40 carbon atoms, divalent groups derived from substituted or unsubstituted arylamines each having 6 to 40 carbon atoms, divalent groups derived from substituted or unsubstituted heterocyclic rings each having 3 to 40 carbon atoms and substituted or unsubstituted ethenylene groups.

The present invention relates to a pharmaceutical composition, a food composition or a cosmetic composition, containing one or more kinds of a compound represented by the following formula (I′)wherein R1 is a hydrogen atom, a hydroxyl group, a methoxy group or an ethoxy group, R2 is a hydroxyl group, a methoxy group or an acetoxy group, or R1 and R2 in combination optionally form a methylenedioxy group,R is represented by the following formulawherein Y is an ethylene group or a vinylene group, m and n are each an integer of 0 to 7, which satisfy m+n=2 to 8, and R3 and R4 are each independently a hydrogen atom, a methyl group or an ethyl group,provided that,(1) when R1 is a methoxy group, then R2 is not a hydroxyl group; and(2) when R1 is a hydroxyl group, then R2 is not a hydroxyl group and an acetoxy group.According to the present invention, a stable capsinoid derivative is provided, and a pharmaceutical composition, a food composition, a cosmetic composition and the like containing the derivative as an active ingredient can be provided.

The present invention relates to microbicides for agricultural or horticultural use containing sulfonamide derivative of, for example, a formula (I): or a salt thereof, [wherein A<1 >is (1) an aryl group which may be substituted or (2) a heterocyclic group which may be substituted, X<1 >is (1) a chemical bond, (2) a methylene group which may be substituted, or (3) a vinylene group which may be substituted, B<1 >is a five-membered heterocyclic group comprising nitrogen or sulfur atoms as the ring-constructing atoms except for carbon atoms and may be substituted or a condensed heterocyclic group which may be substituted, Z<1 >is (1) a hydrocarbon group which may be substituted, (2) an acyl group which may be substituted, (3) formyl group, (4) an amino group which may be substituted, (5) a group represented by -N=CR<1>R<2 >(wherein each of R<1 >and R<2 >is a hydrogen atom or a hydrocarbon group which may be substituted), (6) a cyclic amino group, (7) a group represented by -OR<3 >(wherein R<3 >is a hydrogen atom, a hydrocarbon group which may be substituted, an acyl group which may be substituted, formyl group or an alkylsulfonyl group which may be substituted) or (8) -S(O)nR<4 >(wherein n stands for an integer from 0 to 2, R<4 >stands for a hydrogen atom or a hydrocarbon group which may be substituted). The said compounds or the salts thereof are sulfonamide derivatives with microbicidal action, are useful as excellent microbicides for agricultural or horticultural use, because they are safe, and they have little influence on human beings, farm animals, natural enemies, or the environment, and exert excellent control effects even on resistant microbes.

The present invention relates to a pharmaceutical composition, a food composition or a cosmetic composition, containing one or more kinds of a compound represented by the following formula (I′)wherein R1 is a hydrogen atom, a hydroxyl group, a methoxy group or an ethoxy group, R2 is a hydroxyl group, a methoxy group or an acetoxy group, or R1 and R2 in combination optionally form a methylenedioxy group,R is represented by the following formulawherein Y is an ethylene group or a vinylene group, m and n are each an integer of 0 to 7, which satisfy m+n=2 to 8, and R3 and R4 are each independently a hydrogen atom, a methyl group or an ethyl group,provided that,(1) when R1 is a methoxy group, then R2 is not a hydroxyl group; and(2) when R1 is a hydroxyl group, then R2 is not a hydroxyl group and an acetoxy group.According to the present invention, a stable capsinoid derivative is provided, and a pharmaceutical composition, a food composition, a cosmetic composition and the like containing the derivative as an active ingredient can be provided.

The invention belongs to the technical field of electroluminescent materials, and discloses a compound containing 9,9-spiral thioxanthene as well as a preparation and application. The compound containing 9,9-spiral thioxanthene has the structural formula represented by formula 1 or formula 2, wherein R1 and R2 are the same or different electron-donating vinylene group, ethynylene group, aromatic ring composed of carbon and hydrogen atoms, aromatic heterocyclic ring composed of carbon, nitrogen and hydrogen atoms, aromatic heterocyclic ring composed of carbon, nitrogen, oxide and hydrogen atoms, aromatic heterocyclic ring composed of carbon, sulfur and hydrogen atoms, and aromatic heterocyclic ring composed of carbon, silicon and hydrogen atoms, C1-C24 alkyl group, alkyl-substituted conjugated unit, alkoxy-substituted conjugated unit or conjugated unit in which an alkyl group and an alkoxy group are simultaneously substituted; X is a carbon atom, a nitrogen atom, a sulfur atom, a silicon atom, an oxygen atom, carbonyl or phosphorus atom group. The compound obtained by the invention has fluorescence, and is as the light-emitting layer of an organic electroluminescent diode that can significantly improve the external quantum efficiency of the device. (The formulas are shown in the description).

A pharmaceutical preparation for preventing or treating pruritic symptoms which contains as an effective ingredient a prostaglandin derivative represented by formula [1]wherein X1 and X2 which are different from each other represent a hydrogen atom, a halogen atom or a hydroxyl group; Y is an ethylene group, a vinylene group or an ethynylene group; Z is the formula (CH2)kA(CH2)hB(CH2)q, (CH2)kA(CH2)rA′(CH2)t (CH2)kB(CH2)hB′(CH2)q or (CH2)k-1B′(CH2)q-1A′wherein k is an integer of 1 to 4, h is an integer of 0 to 4, q is an integer 1 to 4, r is an integer of 0 to 4, and t is an integer of 0 to 2; A and A′ which may be the same or different represent an ethylene group, a vinylene group or an ethynylene group; B and B′ which may be the same or different represent an oxygen atom or a group represented by the formula S(O)u wherein u is an integer of 0 to 2; W1 is a hydroxyl group, a C1-10 alkyloxy group, a C3-10 cycloalkyloxy group, an aryloxy group or an arylalkyloxy group; W2 is a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group, a C3-10 cycloalkyl group, a C1-5 alkyl group substituted by C3-10 cycloalkyl group(s), or a group represented by the formula wherein W4 is a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10 alkynyl group or a C1-5 alkyl group substituted by C3-10 cycloalkyl group(s); v is an integer of 0 to 4; W3 is a hydrogen atom or a methyl group, or W3 when taken together with W2 and the adjacent carbon atom forms a C3-10 cycloalkyl group; m is 0 or 1, a pharmaceutically acceptable salt thereof or a hydrate thereof.

A copolymer containing carbazole-based and vinylene based moieties, a photoelectrode comprising a metal oxide substrate and the copolymer as a photoelectrocatalyst component to the photoelectrode, as well as a photoelectrochemical cell including the photoelectrode. Methods of producing the copolymers, and methods of using the photoelectrochemical cell to produce hydrogen gas are also provided.

An external preparation comprising following ingredients (A) and (B): (A) a compound represented by the following general formula (1) wherein R1 represents an organic residue having a cyclic structure that may have a substituent; R2 represents a hydrogen atom or a lower alkyl group; and X represents an ethylene group or an ethenylene group or a salt thereof, and (B) a monoterpene. The external preparation of the present invention is excellent in percutaneous absorbability.

This room-temperature-curable organopolysiloxane composition includes: component (A); 0.1-30 parts by mass of component (B) per 100 parts by mass of component (A); and 0.001-20 parts by mass of component (D) per 100 parts by mass of component (A). Component (A) is an organopolysiloxane represented by general formula (1) (in general formula (1): R1 represents hydrogen, or a substituted or unsubstituted C1-20 monovalent hydrocarbon group; the plurality of R1s may be the same or different; and n represents an integer of at least 1). Component (B) is an organic silicon compound which is represented by general formula (2), and which is characterized by having two silyl-vinylene groups provided to the same silicon atom (in general formula (2): R1 represents hydrogen, or a substituted or unsubstituted C1-20 monovalent hydrocarbon group; the plurality of R1s may be the same or different; R2 represents a substituted or unsubstituted C1-20 alkyl group, or a substituted or unsubstituted C3-20 cycloalkyl group; and a represents an integer from 1 to 3). Component (D) is a curing catalyst.

An optical film having a recurring unit of the following formula (1) with good heat resistance and good optical properties: formula (1) wherein X represents a divalent linking group containing a monocyclic or condensed polycyclic aromatic ring; Y represents a methylene group, an ethylene group or an ethenylene group; and X is represented by the following formula (2), wherein R1 and R2 are each a halogen group, alkyl group, alkoxy group or aryl group, and m and n are each 0-4.

This room-temperature-curable organopolysiloxane composition includes: component (A); 0.1-30 parts by mass of component (B) per 100 parts by mass of component (A); and 0.001-20 parts by mass of component (D) per 100 parts by mass of component (A). Component (A) is an organopolysiloxane represented by general formula (1) (in general formula (1): R1 represents hydrogen, or a substituted or unsubstituted C1-20 monovalent hydrocarbon group; the plurality of R1s may be the same or different; and n represents an integer of at least 1). Component (B) is an organic silicon compound which is represented by general formula (2), and which is characterized by having two silyl-vinylene groups provided to the same silicon atom (in general formula (2): R1 represents hydrogen, or a substituted or unsubstituted C1-20 monovalent hydrocarbon group; the plurality of R1s may be the same or different; R2 represents a substituted or unsubstituted C1-20 alkyl group, or a substituted or unsubstituted C3-20 cycloalkyl group; and a represents an integer from 1 to 3). Component (D) is a curing catalyst.

A lactone derivative represented by the following general formula (I), which has excellent rooting activity; and a plant growth regulator containing the derivative as an active ingredient. (I) [In the general formula (I), R1 and R2 each is hydrogen, halogeno, C1-6 alkyl, or C1-6 alkoxy; A is methylene, vinylene, imino, oxygen, or sulfur; and n is an integer of 1 to 4; provided that when A is imino, then R1 and R2 each is not hydrogen, and when A is oxygen, then both are hydrogen.]

In a photoreceptor including an electroconductive substrate; a photosensitive layer; and a protective layer, the protective layer includes a crosslinked resin having a residual group of a polycarboxylic acid compound and a group having the below-mentioned formula (10), and at least one of a compound having the below-mentioned formula (2) and a compound having the below-mentioned formula (3).wherein each of R5 and R6 independently represents a hydrogen atom, or a substituted or unsubstituted alkyl group having 1 to 3 carbon atoms.wherein each of R7 and R8 independently represents a hydrogen atom, or an alkyl group having 1 to 4 carbon atoms, and Z1 represents a vinylene group, a divalent aromatic hydrocarbon group having 6 to 14 carbon atoms, or a 2,5-thiophenediyl group.wherein each of Ar1 and Ar2 independently represents an aromatic group having 6 to 14 carbon atoms, Z2 represents a divalent aromatic hydrocarbon group having 6 to 14 carbon atoms, and each of R9 and R10 independently represents a hydrogen atom, or a methyl group.

A heteroannelated anthraquinone derivative compound is provided. The heteroannelated anthraquinone derivative compound is represented by a formula (I):wherein R1 is a substituent being one selected from a group consisting of i) a first substituent being one selected from a group consisting of a hydryl group, an amino group, a nitro group, a hydroxyl group and a cyan group, ii) a second substituent being one selected from a group consisting of (CH2)nX, a straight (CH2)n alkyl group, a (CH2)n alkoxyl group, a branched (CH2)n alkyl group, a C3˜C12nephthenic group, and a C3˜C12 cyclic alkoxyl group, wherein 1=n=12, and X is a halogen, iii) a third substituent being one selected from a group consisting of a straight C1˜C8 alkyl group with a double-bond, a C1˜C8 alkoxyl group with a double-bond, a branched C1˜C8 alkyl group with a double-bond and a C3˜C8 nephthenic group with a double-bond, and iv) a fourth substituent of a C5˜C12 heterocyclic group.

Provided are a π-electron conjugated polymer having a constitutional unit represented by general formula (2) that is suitable as an electrochromic material that changes from a desired colored state to a decolored state, a new compound that is a raw material of the polymer, and a method for producing the polymer: wherein each X independently represents one selected from the group consisting of an oxygen atom, a sulfur atom, —NH—, and —NR1— (wherein R1 is an optionally substituted alkyl group having 1 to 20 carbon atoms or an optionally substituted aryl group having 6 to 20 carbon atoms); each Y independently represents an oxygen atom or a sulfur atom; each Z independently represents one selected from the group consisting of a hydrogen atom and optionally substituted organic groups having 1 to 20 carbon atoms, and W is one selected from the group consisting of an ethynylene group, an optionally substituted ethenylene group, optionally substituted arylene groups, and optionally substituted divalent heteroaromatic ring groups; and n is an integer of 2 or greater.

The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I):wherein represents a single bond or a double bond; Ar1 represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R1 and R2 each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z1 represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing Aβ40 and Aβ42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ such as Alzheimer's disease or Down's syndrome.

Provided is a novel fluorene derivative which is useful as a catalyst component for olefin polymerization, a transition metal compound containing the fluorene derivative as a part of ligand, a catalyst for olefin polymerization containing the transition metal compound, and a process for producing olefin polymer. The fluorene derivative is characterized by being represented by the following general formula [I]:wherein R1, R2, R3, R5, R6, R7, R8, R9, R10, R11, R12, and R14 are each selected from hydrogen, a hydrocarbon group, and a silicon-containing group, and may be the same as or different from each other, R4 and R13 are each selected from hydrogen, a hydrocarbon group, a silicon-containing group, a sulfur-containing group, an oxygen-containing group, a nitrogen-containing group, and a halogen-containing group, and may be the same as or different from each other, and adjacent substituents of R1 to R14 may be bonded to each other to form a ring, except that the case where R4 and R5, and R12 and R13 are each bonded to each other to form a vinylene group. Also provided is a bridged metallocene compound having both of the skeleton and a cyclopentadiene skeleton.

An optical film having a recurring unit of the following formula (1) with good heat resistance and good optical properties:wherein X represents a divalent linking group containing a monocyclic or condensed polycyclic aromatic ring; Y represents a methylene group, an ethylene group or an ethenylene group; and X is represented by the following formula (2):wherein R1 and R2 each represent a halogen atom, an alkyl group, an alkoxy group or an aryl group; and m and n each indicate from 0 to 4.

Disclosed is a non-aqueous electrolyte for a lithium secondary battery and a lithium secondary battery comprising the same. The non-aqueous electrolyte including an ionizable lithium salt and an organic solvent may further include (a) 1 to 10 parts by weight of a compound having a vinylene group or vinyl group per 100 parts by weight of the non-aqueous electrolyte, and (b) 10 to 300 parts by weight of a dinitrile compound having an ether bond per 100 parts by weight of the compound having the vinylene group or vinyl group. The lithium secondary battery comprising the non-aqueous electrolyte may effectively suppress the swelling and improve the charge / discharge cycle life.

In order to provide a lithium secondary battery having high terminal-to-terminal open circuit voltage at the end of charge, suppressed amount of evolved gas on continuous charge, and superior cycle characteristics, the electrolyte solution thereof comprises either both vinylethylene carbonate compound and vinylene carbonate compound, lactone compound having a substituent at its α position in an amount of 0.01 weight % or more and 5 weight % or less, lactones having an unsaturated carbon-carbon bond in an amount of 0.01 weight % or more and 5 weight % or less, or sulfonate compound represented by the formula below.In the formula, L represents a bivalent connecting group consisting of at least one carbon atom and hydrogen atoms, and R30 represents, independently of each other, an unsubstituted or fluorine-substituted aliphatic saturated hydrocarbon group.

The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I):wherein represents a single bond or a double bond; Ar1 represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R1 and R2 each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z1 represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing Aβ40 and Aβ42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ such as Alzheimer's disease or Down's syndrome.